GB9426224D0 - Pharmaceutical compounds - Google Patents

Pharmaceutical compounds

Info

Publication number
GB9426224D0
GB9426224D0 GBGB9426224.3A GB9426224A GB9426224D0 GB 9426224 D0 GB9426224 D0 GB 9426224D0 GB 9426224 A GB9426224 A GB 9426224A GB 9426224 D0 GB9426224 D0 GB 9426224D0
Authority
GB
United Kingdom
Prior art keywords
pharmaceutical compounds
pharmaceutical
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GBGB9426224.3A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xenova Ltd
Original Assignee
Xenova Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenova Ltd filed Critical Xenova Ltd
Priority to GBGB9426224.3A priority Critical patent/GB9426224D0/en
Publication of GB9426224D0 publication Critical patent/GB9426224D0/en
Priority to ZA9510909A priority patent/ZA9510909B/xx
Priority to CZ971900A priority patent/CZ190097A3/cs
Priority to BR9510410-0A priority patent/BR9510410A/pt
Priority to SK836-97A priority patent/SK83697A3/sk
Priority to IL11652595A priority patent/IL116525A0/xx
Priority to PCT/GB1995/003027 priority patent/WO1996020190A1/en
Priority to CA002207500A priority patent/CA2207500A1/en
Priority to CN95197672A priority patent/CN1175253A/zh
Priority to EP95941797A priority patent/EP0799222A1/en
Priority to AU43100/96A priority patent/AU698828B2/en
Priority to NZ297847A priority patent/NZ297847A/en
Priority to JP8520301A priority patent/JPH10511384A/ja
Priority to HU9800398A priority patent/HUT77943A/hu
Priority to GB9712184A priority patent/GB2311781B/en
Priority to PL95320916A priority patent/PL320916A1/xx
Priority to SG1995002320A priority patent/SG32534A1/en
Priority to TW084113836A priority patent/TW358094B/zh
Priority to BG101602A priority patent/BG101602A/xx
Priority to FI972660A priority patent/FI972660A/fi
Priority to NO972937A priority patent/NO972937L/no
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB9426224.3A 1994-12-23 1994-12-23 Pharmaceutical compounds Pending GB9426224D0 (en)

Priority Applications (21)

Application Number Priority Date Filing Date Title
GBGB9426224.3A GB9426224D0 (en) 1994-12-23 1994-12-23 Pharmaceutical compounds
ZA9510909A ZA9510909B (en) 1994-12-23 1995-12-21 Pharmaceutical compounds
PL95320916A PL320916A1 (en) 1994-12-23 1995-12-22 Derivatives of piperasino 2,5-dione as modulators of drug-fastness in respect to amny drugs
AU43100/96A AU698828B2 (en) 1994-12-23 1995-12-22 Piperazine 2,5 dione derivatives as modulators of multi-drug resistance
NZ297847A NZ297847A (en) 1994-12-23 1995-12-22 Piperazine-2,5-dione derivatives and their use as medicaments
SK836-97A SK83697A3 (en) 1994-12-23 1995-12-22 Piperazine-2,5-dione derivatives as modulators of multi-drug resistance
IL11652595A IL116525A0 (en) 1994-12-23 1995-12-22 Piperazinedione derivatives their preparation and use
PCT/GB1995/003027 WO1996020190A1 (en) 1994-12-23 1995-12-22 Piperazine 2,5 dione derivatives as modulators of multi-drug resistance
CA002207500A CA2207500A1 (en) 1994-12-23 1995-12-22 Piperazine 2,5 dione derivatives as modulators of multi-drug resistance
CN95197672A CN1175253A (zh) 1994-12-23 1995-12-22 作为多药抗性调节剂的哌嗪－2,5－二酮衍生物
EP95941797A EP0799222A1 (en) 1994-12-23 1995-12-22 Piperazine 2,5 dione derivatives as modulators of multi-drug resistance
CZ971900A CZ190097A3 (cs) 1994-12-23 1995-12-22 Deriváty piperazin-2,5-dionu jako modulátory multidrogové rezistence
BR9510410-0A BR9510410A (pt) 1994-12-23 1995-12-22 Composto, composição farmacêutica ou veterinária, processo para produzir o composto e uso do composto
JP8520301A JPH10511384A (ja) 1994-12-23 1995-12-22 多薬剤耐性のモジュレーターとしてのピペラジン２，５ジオン誘導体
HU9800398A HUT77943A (hu) 1994-12-23 1995-12-22 2,5-Dioxo-piperazin-származékok, eljárás előállításukra és alkalmazásuk, valamint közbenső termékei
GB9712184A GB2311781B (en) 1994-12-23 1995-12-22 Piperazine 2,5 dione derivatives as modulators of multi-drug resistance
TW084113836A TW358094B (en) 1994-12-23 1995-12-23 Piperazinedione derivatives, their preparation and their use as moduators of multi-drug resistance
SG1995002320A SG32534A1 (en) 1994-12-23 1995-12-23 Pharmaceutical compounds
BG101602A BG101602A (en) 1994-12-23 1997-06-11 Pharmaceutical piperazine compounds
FI972660A FI972660A (fi) 1994-12-23 1997-06-19 Piperatsini-2,5-dionijohdannaiset monilääke resistanssi modulaattoreina
NO972937A NO972937L (no) 1994-12-23 1997-06-23 Farmasöytiske piperazinforbindelser

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9426224.3A GB9426224D0 (en) 1994-12-23 1994-12-23 Pharmaceutical compounds

Publications (1)

Publication Number Publication Date
GB9426224D0 true GB9426224D0 (en) 1995-02-22

Family

ID=10766589

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB9426224.3A Pending GB9426224D0 (en) 1994-12-23 1994-12-23 Pharmaceutical compounds

Country Status (19)

Country Link
EP (1) EP0799222A1 (zh)
JP (1) JPH10511384A (zh)
CN (1) CN1175253A (zh)
AU (1) AU698828B2 (zh)
BG (1) BG101602A (zh)
BR (1) BR9510410A (zh)
CA (1) CA2207500A1 (zh)
CZ (1) CZ190097A3 (zh)
FI (1) FI972660A (zh)
GB (1) GB9426224D0 (zh)
HU (1) HUT77943A (zh)
IL (1) IL116525A0 (zh)
NO (1) NO972937L (zh)
NZ (1) NZ297847A (zh)
PL (1) PL320916A1 (zh)
SK (1) SK83697A3 (zh)
TW (1) TW358094B (zh)
WO (1) WO1996020190A1 (zh)
ZA (1) ZA9510909B (zh)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA979329B (en) * 1996-10-18 1999-04-19 Xenova Ltd Pharmaceutical compounds
GB9717576D0 (en) * 1997-08-19 1997-10-22 Xenova Ltd Pharmaceutical compounds
GB9708805D0 (en) 1997-05-01 1997-06-25 Smithkline Beecham Plc Compounds
GB9810876D0 (en) 1998-05-20 1998-07-22 Smithkline Beecham Plc Compounds
CA2346689A1 (en) 1998-10-08 2000-04-20 Gregor James Macdonald Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents)
IL150430A0 (en) * 2000-01-18 2002-12-01 Nereus Pharmaceuticals Inc Cell division inhibitors and process for producing the same
US6693099B2 (en) 2000-10-17 2004-02-17 The Procter & Gamble Company Substituted piperazine compounds optionally containing a quinolyl moiety for treating multidrug resistance
US7919497B2 (en) 2002-08-02 2011-04-05 Nereus Pharmaceuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
US7935704B2 (en) 2003-08-01 2011-05-03 Nereus Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
IL166628A0 (en) 2002-08-02 2006-01-15 Nereus Pharmaceuticals Inc Dehydrophenyl lahistins and analogs thereof and the synthesis of dehydrophenyllahistins and analogs thereof
US8129527B2 (en) 2006-11-03 2012-03-06 Nereus Pharmacuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
CN103396372B (zh) * 2013-08-09 2015-05-20 中国科学院南海海洋研究所 一类2,5-二酮哌嗪衍生物及其制备方法和在制备抗海洋污损生物防除剂中的应用
US10076518B2 (en) 2015-03-06 2018-09-18 Beyondspring Pharmaceuticals, Inc. Method of treating a brain tumor
US10238650B2 (en) 2015-03-06 2019-03-26 Beyondspring Pharmaceuticals, Inc. Method of treating cancer associated with a RAS mutation
MX2018000451A (es) 2015-07-13 2018-05-07 Beyondspring Pharmaceuticals Inc Composiciones de plinabulina.
RU2753543C1 (ru) 2016-02-08 2021-08-17 Бейондспринг Фармасьютикалс, Инк. Композиции, содержащие тукаресол или его аналоги
WO2017214052A1 (en) 2016-06-06 2017-12-14 Beyondspring Pharmaceuticals, Inc. Composition and method for reducing neutropenia
WO2018129381A1 (en) 2017-01-06 2018-07-12 Beyondspring Pharmaceuticals, Inc. Tubulin binding compounds and therapeutic use thereof
JP2020514412A (ja) 2017-02-01 2020-05-21 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド 好中球減少症の低減方法
KR20200112881A (ko) 2018-01-24 2020-10-05 비욘드스프링 파마수티컬스, 인코포레이티드. 플리나불린의 투여를 통해 혈소판감소증을 감소시키는 조성물 및 방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0649410B1 (en) * 1992-07-10 1997-05-02 Laboratoires Glaxo Sa Anilide derivatives
GB9217331D0 (en) * 1992-08-14 1992-09-30 Xenova Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
IL116525A0 (en) 1996-03-31
WO1996020190A1 (en) 1996-07-04
BG101602A (en) 1998-02-27
ZA9510909B (en) 1996-08-30
AU4310096A (en) 1996-07-19
FI972660A0 (fi) 1997-06-19
NO972937D0 (no) 1997-06-23
NO972937L (no) 1997-06-23
TW358094B (en) 1999-05-11
AU698828B2 (en) 1998-11-05
EP0799222A1 (en) 1997-10-08
HUT77943A (hu) 1998-12-28
CA2207500A1 (en) 1996-07-04
JPH10511384A (ja) 1998-11-04
PL320916A1 (en) 1997-11-10
SK83697A3 (en) 1998-05-06
CZ190097A3 (cs) 1998-01-14
BR9510410A (pt) 1999-09-08
NZ297847A (en) 1999-04-29
FI972660A (fi) 1997-08-22
CN1175253A (zh) 1998-03-04

Similar Documents

Publication Publication Date Title
ZA951180B (en) Pharmaceutical compounds
ZA959921B (en) Pharmaceutical compounds
GB9602080D0 (en) Pharmaceutical compounds
GB9410387D0 (en) Pharmaceutical compounds
GB9502861D0 (en) Pharmaceutical compounds
GB2286394B (en) Pharmaceutical compounds
GB9426224D0 (en) Pharmaceutical compounds
GB9609976D0 (en) Pharmaceutical compounds
GB9418326D0 (en) Pharmaceutical compounds
GB9417102D0 (en) Pharmaceutical compounds
EP0923564A4 (en) PHARMACEUTICAL COMPOUNDS
ZA9510903B (en) Pharmaceutical compounds
GB9426080D0 (en) Pharmaceutical compounds
GB9502860D0 (en) Pharmaceutical compounds
GB9415617D0 (en) Pharmaceutical compound
GB9417513D0 (en) Pharmaceutical compounds
GB9406052D0 (en) Pharmaceutical compounds
GB9426092D0 (en) Pharmaceutical compounds
ZA951176B (en) Pharmaceutical compounds
GB9426074D0 (en) Pharmaceutical compounds
GB9425040D0 (en) Pharmaceutical compounds
GB9417526D0 (en) Pharmaceutical compounds
SG32533A1 (en) Pharmaceutical compounds
GB9417514D0 (en) Pharmaceutical compounds
ZA941781B (en) Pharmaceutical compounds